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a b s t r a c t
Neural crest cells (NCC) comprise a multipotent, migratory stem cell and progenitor population that
gives rise to numerous cell and tissue types within a developing embryo, including craniofacial bone and
cartilage, neurons and glia of the peripheral nervous system, and melanocytes within the skin. Here we
describe two novel stable transgenic mouse lines suitable for lineage tracing and analysis of gene
function in NCC. Firstly, using the F10N enhancer of the Mef2c gene (Mef2c-F10N) linked to LacZ, we
generated transgenic mice (Mef2c-F10N-LacZ) that express LacZ in the majority, if not all migrating NCC
that delaminate from the neural tube. Mef2c-F10N-LacZ then continues to be expressed primarily in
neurogenic, gliogenic and melanocytic NCC and their derivatives, but not in ectomesenchymal
derivatives. Secondly, we used the same Mef2c-F10N enhancer together with Cre recombinase to
generate transgenic mice (Mef2c-F10N-Cre) that can be used to indelibly label, or alter gene function in,
migrating NCC and their derivatives. At early stages of development, Mef2c-F10N-LacZ and Mef2c-F10N-
Cre label NCC in a pattern similar toWnt1-Cremice, with the exception thatMef2c-F10N-LacZ and Mef2c-
F10N-Cre speciﬁcally label NCC that have delaminated from the neural plate, while premigratory NCC are
not labeled. Thus, our Mef2c-F10N-LacZ and Mef2c-F10N-Cre transgenic mice provide new resources for
tracing migratory NCC and analyzing gene function in migrating and differentiating NCC independently
of NCC formation.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The discovery of neural crest cells (NCC) is credited to His (His,
1868) and for the past 150 years, NCC have fascinated scientists as a
model system for studying cell speciﬁcation, cell delamination,
epithelia to mesenchymal transformation, cell migration and cell
differentiation. Derived from the neuroectoderm, NCC are a transient
multipotent stem and progenitor cell population that gives rise to a
diverse array of tissues and cell lineages. Within the head NCC give
rise to osteocytes, osteoblasts, chondrocytes and chondroblasts of
craniofacial bone and cartilage (Le Lievre and Le Douarin, 1975; Noden,
1982) odontoblasts of the teeth (Achilleos and Trainor, 2012; Chai
et al., 2000), neurons and glia of the peripheral nervous system (PNS)
(D'Amico-Martel and Noden, 1983), the meninges covering the surface
of cerebral cortex (Jiang et al., 2002; Yoshida et al., 2008), smooth
muscle cells of the craniofacial vasculature (Etchevers et al., 2001), and
myoblasts of the extrinsic ocular muscles (Noden, 1983). Other NCC
derivatives include chromafﬁn cells of the adrenal medulla (Jiang
et al., 2000) and melanocytes in the skin (Jiang et al., 2000).
In mouse, analyses of migrating NCC traditionally relied upon
classic histological stains and dye labeling of cultured embryos
(Nichols, 1986; Osumi-Yamashita et al., 1994, 1996; Tam and
Trainor, 1994; Trainor and Tam, 1995). More recently genetic
approaches using transgenic or homologous recombinant repor-
ters have come to the fore. These modern molecular approaches
utilize promoters and enhancers that drive gene expression in NCC
to indelibly label them or to alter gene function therein. Some of
the lines used for these purposes include a knock-in into the 30
untranslated region of the Activator protein 2 alpha transcription
factor locus; AP2α-IRES-Cre (Macatee et al., 2003), human tissue
plasminogen activator promoter; Ht-PA-Cre (Pietri et al., 2003),
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myelin protein zero promoter; P0-Cre (Yamauchi et al., 1999),
knock-in at Paired box family 3 locus; Pax3-Cre (Li et al., 2000);
PAC transgene insertion of Sox (SRY-related HMG-box) family
transcription factor 10 locus; Sox10-Cre (Matsuoka et al., 2005),
Wnt1 promoter and enhancer; Wnt1-Cre (Chai et al., 2000) and
Tyrosinase enhancer and promoter; Tyrosinase-Cre (Tonks et al.,
2003).
Of the Cre drivers available for analyses of NCC, the Wnt1-Cre
transgenic mouse line exhibits the most robust and consistent activity
within NCC and their derivatives and thus has become the standard
for lineage tracing and investigation of gene function in NCC (Brault et
al., 2001; Chai et al., 2000; Danielian et al., 1998; Jiang et al., 2000).
However,Wnt1-Cre is expressed in the dorsal neuroepitheliumwhich
encompasses the territory in which NCC are induced to form. There-
fore, Wnt1-Cre cannot distinguish effects in premigratory NCC from
delaminated migratory NCC and does indeed elicit effects in premi-
gratory and migratory NCC as well as in dorsal brain tissue (Brault
et al., 2001; Chai et al., 2000; Jiang et al., 2000; Lewis et al., 2013).
Many of the other Cre transgenic mice that have been used for
analyses of NCC have confounding properties of expression in non-
NCC-derived tissue and/or lack of expression in some NCC lineages
(Hari et al., 2002; Lee et al., 2013; Li et al., 2000; Macatee et al., 2003;
Pietri et al., 2003). Thus, in order to speciﬁcally investigate migratory
NCC and their derivatives independently of premigratory NCC within
the neural plate and to investigate gene function during NCC migra-
tion independently of NCC formation, new mouse lines are needed.
The Myocyte-speciﬁc enhancer factor 2C (Mef2c) gene is
expressed broadly in the developing mouse embryo, including in
NCC (Edmondson et al., 1994; Potthoff and Olson, 2007; Verzi
et al., 2007). Furthermore, tissue speciﬁc conditional inactivation
of Mef2c in NCC via Wnt1-Cre, illustrates that Mef2c is important
for NCC-dependent craniofacial and melanocyte development
(Agarwal et al., 2011; Verzi et al., 2007). Analyses of cis-regul-
atory sequences in theMef2c locus in transient transgenic embryos
identiﬁed an enhancer element called F10N (Mef2c-F10N) that
marked migrating NCC in embryonic day (E) 9.5 embryos (De
Val et al., 2008).
In this study, we used the Mef2c-F10N enhancer to establish new
tools and resources for studying NCC development and function.
Firstly, we made a stable version of the transgenic lacZ reporter line
(Mef2c-F10N-LacZ) and secondly, a transgenic Cre recombinase line
(Mef2c-F10N-Cre). We observed the Mef2c-F10N-LacZ reporter to
initially mark all or nearly all NCC that delaminate from the neuroe-
pithelium. Mef2c-F10N-LacZ expression then subsequently becomes
restricted primarily to neurogenic, gliogenic and melanocytic lineages
of the NCC but not ectomesenchymal derivatives. TheMef2c-F10N-Cre
line induces recombination in a similar pattern when mated with
Rosa26 LacZ reporter mice (R26R). Mef2c-F10N-Cre indelibly labels
migrating NCC and their derivatives in the head (bone, cartilage,
cranial nerve and connective tissue), heart, trunk, (neurons and glia,
thymus and adrenal gland cells) and skin (melanocytes) during emb-
ryonic development. Thus, our Mef2c-F10N transgenic mice provide
useful new tools and resources for tracing and analyzing gene function
during NCC migration and differentiation, independently of NCC for-
mation.
Results
Mef2c-F10N-LacZ speciﬁcally marks migrating neural crest cells in
early E8–9 embryos, becoming limited to neuronal, glial and
melanocyte lineages after E11
The F10N enhancer was originally identiﬁed as a 1227 base pair
fragment (chromosome 13qC3; 83,583,444–83,584,687) in intron
5 of the mouse Mef2c, (also known as MADS box transcription
enhancer factor 2 polypeptide C) locus (Fig. 1A). In E9.5 transient
transgenic mouse embryos, this enhancer appeared to mark
migrating NCC (De Val et al., 2008). Comparative sequence analysis
indicates that the Mef2c-F10N enhancer is highly conserved in
human, mouse, rat, rabbit and chicken, but not in aquatic species
(Fig. 1B). In order to establish new genetic tools for investigating
fate and function of NCC, we sought to establish stable transgenic
lines with a Mef2c-F10N NCC speciﬁc pattern. Therefore a Mef2c-
F10N-LacZ construct (Fig. 1C) was injected into pronuclei of one
cell stage CBA; B10 F1 hybrid embryos and three stable mouse
lines were established. Presence of the Mef2c-F10N-LacZ transgene
was conﬁrmed by PCR genotyping. Expression of Mef2c-F10N-LacZ
in the newly established lines was examined via whole-mount
X-gal staining of embryos at various developmental stages. In
E7.0–7.5 gastrulation stage embryos Mef2c-F10N-LacZ is detected
in extraembryonic tissues surrounding the exocoelomic cavity
including the allantois, but β-galactosidase activity was not pre-
sent in the embryonic epiblast that gives rise to the embryo
(Fig. 1D–F). Beginning around E8.0–8.5 (5 somite stage), Mef2c-
F10N-LacZ expression appeared in embryonic tissues resembling
cranial NCC as they delaminate from the dorsal neuroectoderm
(Fig. 1G and H, red outline arrowheads). Mef2c-F10N-LacZ con-
tinued to be expressed in a pattern consistent with the stereo-
typical streams of cranial NCC that colonize the pharyngeal arches
(Fig. 1H, red arrows). In E9.5 embryos, Mef2c-F10N-LacZ continued
to label NCC that colonized the craniofacial primordia, including
the frontonasal mass (FNM) and pharyngeal arches (Fig. 1I, arrow-
heads). Some scattered Mef2c-F10N-LacZ labeled cells however
remained in association with the dorsal midbrain (Fig. 1I and K
yellow arrows). Furthermore, Mef2c-F10N-LacZ expression in the
cardiac, vagal and trunk NCC populations was also clearly evident
at this stage. These results suggest that Mef2c-F10N-LacZ marks
migrating neural crest cells but does not label premigratory NCC
within the neuroepithelium.
In E10.5 embryos (Fig. 1J–L), Mef2c-F10N-LacZ was strongly
expressed in NCC-derived facial mesenchyme including the medial
and lateral nasal processes and pharyngeal arches. Mef2c-F10N-
LacZ expression was also apparent within the cardiac outﬂow tract
(Fig. 1L, open red arrow), in trunk DRG (Fig. 1J and L) and in the
vagal region where NCC enter the gastrointestinal tract (Fig. 1L,
closed red arrows). At no stage was expression observed within
the neural tube. These results suggest that Mef2c-F10N-LacZ marks
migrating NCC but does not label premigratory NCC within the
neuroepithelium.
Whereas Mef2c-F10N-LacZ expression corresponds to migrating
NCC during early stages of embryonic development, from E11.5
onward transgene expression became more reﬁned. β-galactosidase
activity was no longer observed in ectomesenchymal or cardiac NCC.
Instead, Mef2c-F10N-LacZ expression appeared to be limited to
neuronal and glial NCC derivatives in cranial nerves and the trunk
PNS (Fig. 1M–O, Fig. 2, Supplementary Fig. 1). Enhancer activity
corresponded to the location of known NCC derivatives in the enteric
ganglia of the gut (Fig. 1M–O, Fig. 2D, red arrow). At E12.5 transgene
expression was detected in the region of the thymus (Fig. 1N and
Fig. 2D, blue arrowheads). Expression was also observed in a pattern
consistent with that of putative melanocyte progenitors, which
migrate into the cranial and vagal region as early as E10.0
(Adameyko et al., 2012) (Fig. 1K–O, Fig. 2E–H, Fig. 3B and F,
Supplementary Fig. 1G and H, yellow arrows). The distribution of
Mef2c-F10N-LacZ expressing presumptive melanocytes at E10.5 and
E11.5 suggests that these cells are derivatives of the scattered cells
detected within the midbrain of E9.5 embryos (Fig. 1I, yellow arrows).
The arrangement and location of X-gal stained cells in the facial and
trunk epidermis of E11.5–12.5 embryos (Fig. 2E–H, yellow arrows) is
consistent with the known distribution of melanocytes at these stages
(Mayer, 1973). Together, these results suggest that between E11.5–13.5,
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Mef2c-F10N-LacZ expression becomes restricted to the NCC derivatives
of the neural and glial lineages within the PNS and to the melanocyte
lineage (Fig. 1M–O and Fig. 2A–D).
While staining of whole embryos suggested that Mef2c-F10N-LacZ
was expressed in cranial, cardiac and gut NCC, in order to properly
validate the identity of the cells expressing Mef2c-F10N-LacZ, we
Fig. 1. Mef2c-F10N-LacZ expression corresponds to delaminating and migrating NCC in whole mount embryos. (A) Schematic representation of the F10N enhancer element in
mouseMef2c locus in intron 5 between Exon 5 (Ex5) and Exon 6 (Ex6) on chromosome 13 (Chr13). (B) Analysis of sequence conservation of the Mef2c-F10N enhancer among
rat, rabbit, human, chicken, Xenopus tropicalis and zebraﬁsh. (C) Schematic of Mef2c-F10N-LacZ transgene construct composed of the F10N enhancer, heat shock protein 68
(Hsp68) minimal promoter, a cDNA encoding β-galactosidase (LacZ) and SV40 polyadenylation signal sequences (pA). (D–O) Mef2c-F10N-LacZ embryos whole mount stained
for β-galactosidase activity at progressive stages of development reveal the expression pattern of Mef2c-F10N-LacZ. At early gastrulation stages, expression is observed in
extraembryonic tissues. At the onset of NCC migration Mef2c-F10N-LacZ is expressed in NCC newly delaminated form the neural ectoderm. Later, expression persists in NCC
and neurogenic, gliogenic and melanocyte derivatives. (D) Lateral view of E7 late bud stage (LB). (E) Lateral view of E7 late head fold stage (LHF) embryo and (F) axial view of
exocoelomic cavity opened at red dashed line in (E), allantois (white arrowhead). (G) Lateral view of E8.0, 5 somite stage embryo, in which β-galactosidase activity
corresponds to NCC newly delaminated from the neural ectoderm. (H) E8.5, 8–9 somite stage embryos with expression apparent in pre-otic, post-otic and vagal NCC streams.
(I) E9.5, 21-somite stage embryo with transgene expression in NCC of the fronotnasal mass, pharyngeal arches, and anterior trunk. (J) E10.5, 32-somite stage embryo with
expression in developing facial tissues and trunk PNS. (K–L) Enlarged images of regions outlined in (J). (K) Transgene expression in NCC-ﬁlled prominences of the developing
face, and in trigeminal ganglion and melanocytes. (L) Transgene expression is apparent in the cardiac outﬂow tract, ENS and DRG. (M–O) At E11.5 and later stages of
development expression is observed in PNS, ENS and melanocytes. (M) E11.5 (N), E12.5 and (O) E13.5. White-red arrowheads indicate pre-otic, postotic and vagal NCC
streams. Red solid tailed arrows indicate migrating ENS NCC. Red open tailed arrow, cardiac outﬂow tract. Yellow–black outlined arrows, presumptive melanocyte
progenitors or melanocytes. Blue arrowhead indicates location of thymus. Abbreviations: A, anterior; DRG, dorsal root ganglia; E, eye, FL, fore limb; FNM, frontonasal mass;
H, heart; HL, hind limb; LNP, lateral nasal process; MNP, medial nasal process; Md, mandibular process; Mx, maxillary process; N, node; P, posterior; POS, post-otic sulcus; so,
somites Tg, trigeminal ganglion. Scale bars: 0.2 mm in D–H, 1 mm in I–O.
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performed section immunohistochemistry to visualize LacZ expres-
sion with an anti-β-galactosidase antibody in conjunction with stan-
dard markers of NCC. To detect NCC we used antibodies against, SOX9,
SOX10, and AP2α (Fig. 3). In order to identify mesodermal cells within
the core of developing pharyngeal arches, we stained for the LIM
homeodomain transcriptional factors, Islet1/2 (ISL1/2). Double immu-
nostaining indicates that Mef2c-F10N-LacZ was expressed in NCC
derivatives within the mesenchyme of facial primordia (Fig. 3A–C
Fig. 2. Mef2c-F10N-LacZ expression pattern corresponds to PNS and melanocyte NCC lineages. (A–D) Whole-mount E12.5 X-gal stained embryos. Lateral (A, B), and frontal
(C–D) images of whole embryo (A), head (B–C), and trunk (D). Red arrow indicates ENS NCC staining. Blue arrowheads indicate the location of the thymus. Mef2c-F10N-LacZ
expression is apparent in the cranial PNS, trunk PNS, the thymus, and the ENS of the gut. (E–H) Section images of the face (E) and trunk (G) at the level of long red dashed line
in (A). (F, H) High magniﬁcation images of red dashed insets in (E) and (G), respectively. Transgene expression is detected in epidermal cells in a distribution corresponding to
melanocytes, yellow arrows. Abbreviations: DRG, dorsal root ganglion; IV, trochlear nerve; E, eye; Md.V, mandibular brunch of trigeminal nerve; Mx,V, maxillary brunch of
trigeminal nerve; ON, olfactory nerve; Op.V, ophthalmic brunch of trigeminal nerve; SG, sympathetic ganglion; T, tongue; Tg, trigeminal ganglion; VII facial nerve; X, vagus
nerve. Scale bars: 1 mm in A–H.
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and E–G). Importantly there was a clear segregation of transgene exp-
ression from the ISL1/2 expressing mesodermal core of the mandib-
ular process (Fig. 3C, yellow arrowhead). Mef2c-F10N-LacZ was co-
expressed with SOX9/10 and AP2α markers in migrating cardiac NCC
(Fig. 3D and H, white arrow). Expression of β-galactosidase overlapped
with that of SOX10 and AP2α at the entrance to the foregut (Fig. 3G
and I), indicating that the Mef2c-F10N-LacZ transgene is expressed in
vagal NCC progenitors within the enteric nervous system (ENS) as
well. Thus, taken together, these data reveal that Mef2c-F10N-LacZ
expressing cells which appear in a stereotypical NCC distribution as
early as E8.0 are cranial, cardiac and vagal NCC.
Within the trunk region of the embryo, NCC are known to con-
tribute to neuronal and glial cells of the PNS, including the ENS of the
gut, sympathetic ganglia (SG), dorsal root ganglia (DRG), and they also
give rise to melanocytes (Jiang et al., 2000) (Fig.4). To examine
whether Mef2c-F10N-LacZ demarcates NCC within the trunk region
as it does in the head, and to determine if it labels neural and/or glial
fated NCC, we performed immunohistochemistry on transverse sec-
tions from the trunk level of E9.5–10.5 embryos (Fig. 4A–J). Mef2c-
F10N-LacZ-positive cells co-stained with SOX10 and AP2α, indicating
that the transgene is expressed in NCC in the trunk as it is in the head
(Fig. 4A–D and G–J). Msh homeobox 1/2 (Msx1/2) and Paired box
protein 3 and 7 (PAX3 and PAX7) are expressed in the dorsal
neuroepithliumwhere they label premigratory NCC, and they are also
expressed in migrating NCC after delamination (Murdoch et al., 2012).
Mef2c-F10N-LacZ labeling overlapped with MSX1/2 and PAX3/7, but
only in migrating NCC. (Fig. 4E and F). Although we cannot absolutely
rule out the occasional Mef2C-F10N-LacZ positive premigratory or
delaminating neural crest cell, the fact that MSX1/2 and PAX3/7-
positive cells within the neuroepithelium, which include premigratory
NCC were not stained for β-galactosidase, indicates that in the trunk,
as in the head,Mef2c-F10N-LacZ speciﬁcally labels migratory NCC that
have delaminated from the neuroepithlium.
Within the PNS of the trunk, NCC contribute to both neuronal
and glial cell lineages. Neurons of the DRG, derived from NCC can
be identiﬁed by expression of Neuroﬁlament (NF), Nerve growth
factor receptor, (NGFR, known as p75) and neuron-speciﬁc class III
β-tubulin (Tuj1) (Fig. 4A, B and G–J). Immunostaining for each of
these molecules reveals the presence of cells in developing DRG
co-labeled with β-galactosidase and each of the neuronal markers,
demonstrating that Mef2c-F10N-LacZ labels NCC derived neurons
in the PNS (Fig. 4A, B and G–J). Similarly at later embryonic stages,
Mef2c-F10N-LacZ labeled cells co-stained with Tuj1 in cranial and
trunk peripheral nerves (Fig. 2 and Supplementary Fig. 1). These
results indicate that the Mef2c-F10N enhancer labels migrating
NCC after their delamination from the neuroepithelium and
continues to label NCC fated to become neurons within the PNS
(Fig. 4K).
It is important to note that we have not observed β-galactosidase
expression in skeletal derivatives even as early as E12.0 (Fig. 2) nor in
skeletal tissues in older E15.5 and E18.5 embryos. Thus Mef2c-F10N-
LacZ must be switched off in putative ectomesenchyme prior to any
Fig. 3. Mef2c-F10N-LacZ labels facial mesenchyme, cardiac and gut NCC. (A–H) Frontal sections of E9.5 Mef2c-F10N-LacZ embryos at the level of the eye primordium and
Rathke's pouch (A, E) as indicated in Fig. 1I. Triple ﬂuorescence staining with NCC markers, SOX9, ISL1/2, SOX10 and AP2α. (C, D, G, H) Enlarged images of areas identiﬁed by
white dashed insets in A, E, F. Yellow tailed arrows indicate isolated melanocytes under head epithelium. Yellow arrowheads indicate ISL1/2 positive mesenchymal core.
White arrows indicate cardiac NCC. (I) Triple staining of frontal foregut sections. DAPI is used to stain nuclei. Abbreviations: 2nd, second pharyngeal arch; DA, dorsal aorta; E,
Eyes; FB, forebrain; FG, foregut; H, heart; MB, midbrain; Md, mandibular process; Mx, maxillary process; Rp, Rathke's pouch; SG, sympathetic ganglion. Scale bars: 0.2 mm.
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mesenchymal condensation. These observations are consistent with
Mef2c-F10N-LacZ labeling migratory neural crest cells and their neu-
rogenic, but not mesenchymal derivatives.
Comparison of Mef2c-F10N-LacZ transgenic embryos and Wnt1-Cre;
R26R and Rosa-YFP embryos
To further validate the utility of the Mef2c-F10N-LacZ line in labe-
ling NCC and their derivatives, we compared its pattern of expr-
ession to that generated when Wnt1-Cre is crossed to Rosa26R Cre-
dependent reporter lines, which has been widely used for genetic
tracing of NCC lineages, cell fate speciﬁcation and gene function. E8.5–
9.5 Mef2c-F10N-LacZ embryos exhibit a remarkably similar staining
patterning toWnt1-Cre;R26R embryos, with the exception thatMef2c-
F10N-LacZ labels only migrating NCC (Fig. 5A, C, and I), whereasWnt1-
Cre;R26R marks the dorsal neural plate and premigratory NCC in
addition to migratory NCC (Fig. 5B, D, F, and J red line and bracket). In
E8.5 embryos both transgenes mark NCC that were delaminating from
the forebrain and midbrain neuroepithelium (Fig. 5A–D), but Wnt1-
Cre;R26R additionally labels the dorsal neuroepithelium (Fig. 5B red
line and Fig. 5D red bracket).
In developing craniofacial tissues of Mef2c-F10N-LacZ embryos,
labeled cells primarily populated the frontonasal process and
pharyngeal arches (Fig. 5E red arrowheads), while in contrast,
labeled cells inWnt1-Cre;R26R embryos populated the entire head,
including the frontonasal process and pharyngeal arches (Fig. 5F
red arrowheads). In E9.0 embryos, NCC migrating into the trunk
region were labeled to a similar extent by both transgenes (Fig. 5E
and F). However, the midline region of the frontonasal process,
brain and spinal cord did not stain in Mef2c-F10N-LacZ embryos,
but does stain in Wnt1-Cre;R26R embryos (Fig. 5G–J). These data
are consistent with the observation that Mef2c-F10N-LacZ speciﬁ-
cally marks migrating NCC after delamination, in contrast toWnt1-
Cre;R26R which labels the dorsal neuroepithelium and conse-
quently premigratory NCC, as well as migratory NCC
To more precisely determine the extent of overlapping expression
between Mef2c-F10N-LacZ and Wnt1-Cre-labeled cells, we assessed
the expression of Mef2c-F10N-LacZ within the background of Wnt1-
Cre;RYFP (ROSA-yellow ﬂuorescent protein) embryos. In cranial tissues
of E10.5 embryos, Mef2c-F10N-LacZ was expressed in NCC derived
facial mesenchyme and cranial nerves (Fig. 5K, M, and O) in a pattern
very similar to that of Wnt1-Cre;RYFP (Fig. 5L, N, and P). In the trunk,
Mef2c-F10N-LacZ was expressed in migrating NCC contributing to the
DRG and the gastrointestinal tract in a pattern similar to Wnt1-Cre;
RYFP (Fig. 5Q–S). Consistent with previous observations, Wnt1-Cre;
RYFP embryos also exhibited expression in the dorsal regions of the
Fig. 4. Mef2c-F10N-LacZ marks migrating neural crest cells in trunk region. (A–J) Transverse sections ofMef2c-F10N-LacZ embryos immunostained for β-galactosidase (β-gal)
and NCC markers, SOX10, AP2α, MSX1/2, PAX3, PAX7 and differentiated neuronal markers, neuroﬁlament (NF), p75-NGF receptor (p75) at E9.5 and E10.5. (B, D, F, H, J)
Enlarged images of insets identiﬁed by white dashed squares in (A, C, E, G, I). DAPI was used to stain nuclei. White arrows indicate overlapping expression. (K), Summary of
Mef2c-F10N-LacZ expression relative to sequential expression of markers of migrating NCC after delaminating from dorsal neural tube. Abbreviations: DA, dorsal aorta; DRG,
dorsal root ganglion; Gt, gut; H, heart; SG, sympathetic ganglion. Scale bars: 0.1 mm.
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brain and spinal cord (Fig. 5L, N, P, Q, and R), whereas Mef2c-F10N-
LacZ did not (Fig. 5K–R). Thus,Mef2c-F10N-LacZ is expressed in NCC in
a manner highly overlapping with that theWnt1-Cre lineage map, but
is speciﬁc for migratory NCC that have delaminated form the neu-
roepithelium.
Mef2c-F10N-Cre transgene permanently marks delaminated
migrating neural crest cells
To expand the utility of the Mef2c-F10N enhancer and to allow
for indelible labeling or genetic modiﬁcation of all migrating and
Fig. 5. Mef2c-F10N-LacZ marks cells in a pattern very similar to Wnt1-Cre but is speciﬁc for migratory NCC. (A-J) Comparison between Mef2c-F10N-LacZ (A, C, E, G, I)
expression andWnt1-Cre;R26R lineage marking (B, D, F, H, J) in whole embryos. Distribution of β-galactosidase activity in lateral (A, B, E, F), frontal (C, D, G, H) and dorsal (I, J)
views of E8.5, 6-somite stage (A–D) and E9.0, 16-somite stage (E–J) embryos. Red outline arrowheads indicate pre-otic NCC streams. (K–P) Frontal sections of E10.5 Mef2c-
F10N-LacZ and Wnt1-Cre;Rosa-YFP compound embryos. Mef2c-F10N-LacZ expression is revealed by β-galactosidase activity (K, M, O), and Wnt1-Cre;YFP lineage marking is
revealed by immunostaining for YFP in conjunction with the endothelial marker CD31, and the neural marker Tuj1. Red arrowheads indicate NCC of dorsal forebrain that may
contribute to the meninges. Red tailed arrows indicate delaminating olfactory nerve from the olfactory epithelium. White arrows indicate the overlap with migrating NCC.
(Q–S) Double staining of β-galactosidase expression from the Mef2c-F10N-LacZ transgene and YFP expression fromWnt1-Cre;Rosa26YFP/þ in neural tube (Q, R) and gut (S) in
E10.5 embryos. (R) High magniﬁcation images of white dashed inset in (Q). White arrows indicate the overlap with migrating NCC. DAPI is used to stain nuclei.
Abbreviations: 2nd second pharyngeal arch; 3rd pharyngeal arch; DA, dorsal aorta; E, eye; FB, forebrain ventricle; G, gut; H, heart; HB, hindbrain; LNP, lateral nasal process;
Md, mandibular process; Mx, maxillary process; MNP, medial nasal process No, notochord; RP, Rathke's pouch; So, somite; SG, sympathetic ganglion; 3rd, third pharyngeal
arch; TG, trigeminal ganglion. Scale bars: 0.5 mm in A–P, 0.1 mm in Q–S.
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differentiating NCC independently of premigratory NCC within the
dorsal neuroepithelium, we constructed a Cre transgene using the
Mef2c-F10N enhancer (Fig. 6A). Mef2c-F10N-Cre transgenic mice
were generated via pronuclear injection of one cell CBA; B10 F1
hybrid embryos. Six Cre positive founder lines were produced. To
check the activity of the Mef2c-F10N-Cre lines, we mated each
founder line with R26R reporter mice and analyzed for spatio-
temporal activity at multiple developmental stages (Fig. 6A). Two
founder lines (#2 and #5) indelibly labeled migrating NCC and
their derivatives (Fig. 6B, C and Supplementary Fig. 2). The freq-
uency of inherited transgene expression in Line 2 and Line 5 was
46.9% (15/32) and 6.61% (8/121), respectively. Line 2 exhibited
some non-NCC associated labeling in the heart and forelimb
(Supplementary Fig. 2). Therefore, we used Mef2c-F10N-Cre line
5 (Fig. 6) for the subsequent detailed analysis of NCC and their
derivatives (Figs.7–10).
Mef2c-F10N-Cre labeled NCC contribute to numerous organs and
tissues
NCC contribute to many tissues and organs throughout the body.
To validate Mef2c-F10N-Cre as a useful line for indelibly labeling
migrating and differentiating NCC, we characterized the distribution
of labeled cells inMef2c-F10N-Cre;R26R embryos throughout gestation.
In frontal sections of E14.5Mef2c-F10N-Cre;R26R embryos (Fig. 7A and
B), many cell types were stained with X-gal. Mef2c-F10N-Cre;R26R
marked the cornea of the eye, trigeminal ganglion, tooth mesenchyme,
whisker pad and Meckel's cartilage (Fig. 7C–H). The mesenchymal cell
labeling in these facial tissues was consistent with NCC lineage tracing
in Wnt1-Cre and other NCC-speciﬁc reporter mice.
NCC give rise to olfactory ensheathing glial cells that support
olfactory axons projecting to the olfactory bulb (Barraud et al.,
2010). Moreover, some reports have also suggested that NCC
invade the olfactory epithelium and contribute to olfactory neu-
rons (Forni et al., 2011; Katoh et al., 2011). E14.5 Mef2c-F10N-Cre;
R26R embryos exhibit β-galactosidase expression within the olfac-
tory bulb, and the mesenchyme surrounding the olfactory epithe-
lium, but not the olfactory epithelium itself (Fig. 8A–D). Of the
β-galactosidase expressing cells in the olfactory bulb most were
negative for Tuj1 (Fig. 8C). The lack of overlapping β-galactosidase
expression and neuronal maker expression in the olfactory bulb
suggests that NCC do not invade the olfactory epithelium to
become neurons, but instead contribute primarily to the olfactory
ensheathing glial cell lineage in the peripheral and central olfac-
tory region (Fig. 8D).
NCC contribution to the cranial vault and brain as assessed using
Wnt1-Cre;R26R mice or chicken-quail chimeras indicates that the
frontal bone and a portion of the interparietal bone of the calvaria, and
the meninges (dura, arachnoid and pia mater) of the forebrain are
NCC-derived (Etchevers et al., 2001; Jiang et al., 2002; Siegenthaler
and Pleasure, 2011). To check whether Mef2c-F10N-Cre marks a
similiar set of NCC derivatives, we performed whole-mount X-gal
staining in conjunction with Alizarin red staining to identify bone.
Staining of E18.5 Mef2c-F10N-Cre;R26R embryos revealed the frontal
bone was strongly β-galactosidase positive, and labeled cells were
evident in the coronal suture (Fig. 9A–D). However, it is evident
histologically that neither the parietal nor interparietal bones were
labeled Sections of embryos immunostained for Tuj1/DAPI revealed
that NCC contribute to the meninges surrounding the forebrain
derived cortex (Fig. 9A and C–E, red arrowheads) and choroid plexus
(Fig. 9F, white arrows). These results are consistent with other
analyses of neural crest cells (Chai et al., 2000; Kague et al., 2012;
Matsuoka et al., 2005; Noden, 1978; Sailer et al., 2005; Sternberg et al.,
2014). Thus, cranial NCC labeled byMef2c-F10N-Cre-labeled contribute
to the frontal bone and meninges of cortex and diencephalon, but not
the parietal and interparietal bones, nor to the meninges of the
midbrain.
We also explored the distribution of Mef2c-F10N-Cre-labeled NCC
in the trunk of E14.5 embryos. Here we observed β-galactosidase
positive cells in dorsal root ganglia (DRG), sympathetic ganglia, in the
thymus, and in smooth muscle cells of the aortic arches (Fig. 10A and
B). In the heart, Mef2c-F10N-Cre labeled NCC were observed in the
mesenchyme at the base of the conotruncus and in the forming
semilunar valve leaﬂets (Fig. 6F and Fig. 10C–E). Mef2c-F10N-Cre
labeled NCC also contributed to the aortic arch and ductus arteriosus
(Fig. 6D and E). Earlier in E10.5 embryos, β-galactosidase positive cells
are clearly evident migrating through the outﬂow tract of the heart
(Fig. 6C). NCC labeled by Mef2c-F10N-Cre also populated the medulla
of the adrenal gland, where they co-stained with the chromafﬁn
cell marker, tyrosine hydroxylase (TH) and the neural intermediate
Fig. 6. Mef2c-F10N-Cre Line 5. (A, B) E9.5 and (C) E10.5 Mef2c-F10N-Cre;R26R embryos stained for β-galactosidase activity illustrating the pattern of migrating NCC
contribution to the head, heart and trunk. Black arrow indicates labeled cells in the heart (C). Mef2c-F10N-Cre labeled NCC also contribute to the aortic arch and ductus
arteriosus (arrows in D, E), and valve leaﬂets (arrow in F) in E14.5 Mef2c-F10N-Cre;R26R embryos. Scale bars: 1 mm.
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ﬁlament marker, neuroﬁlament (NF) (Fig. 10F). Furthermore, Mef2c-
F10N-Cre-labeled NCC also contribute to the nerves of the forelimbs
and hindlimbs (Fig. 10G and H) and to the ENS of the gut, where they
co-stained with the autonomic neuron marker, paired-homeodomain
transcriptional factor (PHOX2B) (Nagashimada et al., 2012) the differ-
entiated neuron marker Tuj1 (Fig. 10I and J), the glial marker SOX10,
and neuroﬁlament protein (NF) (Fig. 10K and L). Thus, theMef2c-F10N-
Cre lineage includes migrating trunk NCC and their stereotypical
derivatives.
Discussion
Several transgenic lines have been generated for lineage tracing
and analyses of gene function in NCC. However, some of these lines
have non-NCC speciﬁc expression and gene activity or other unw-
anted characteristics. For example, the widely used Wnt1-Cre mice
exhibit dorsal cranial and trunk neuroepithelial expression (Fig. 5L, N,
P, Q, and R). Furthermore, although a new version of Wnt1-Cre has
been generated termed Wnt1-Cre2 (Lewis et al., 2013), the widely
used original version of theWnt1-Cre transgenic line exhibits elevated
Wnt signaling mediated by Wnt1 coding sequence in the transgenic
construct (Lewis et al., 2013). Other Cre lines that label migrating NCC
additionally express in cells other than NCC. For example, Sox10-Cre
labels non-NCC derivatives in the cochlea owing to its expression in
the otic vesicle (Jacques-Fricke et al., 2012) and P0-Cre labels non-NCC
derivatives in the brain. The activity of these Cre lines makes them less
than ideal for lineage tracing of NCC and for analyses of gene function
in migratory and differentiating NCC independently of NCC formation.
Thus new tools that enable labeling or genetic modiﬁcation speciﬁ-
cally within NCC are needed.
Here we describe two novel transgenic lines Mef2c-F10N-LacZ and
Mef2c-F10N-Cre, which mark migrating NCC after delamination from
the neural tube. Aside from the distinction between pre-migratory
Fig. 7. TheMef2c-F10N-Cre lineage includes cranial NCC derivatives. (A, B) Frontal sections of E14.5Mef2c-F10N-Cre;R26R embryos at the level of the nasal region (A), and eye
(B) stained for β-galactosidase activity. (C–F) Triple ﬂuorescence staining of cells marked by Cre excision in Mef2c-F10N-Cre embryos (β-β-galactosidase), mature neurons
(Tuj1), endothelial cells (CD31), or collagen ΙΙ (Col ΙΙ) to identify cartilage. Mef2c-F10N-Cre lineage labeled cells are present in the cornea of the eye (C), trigeminal ganglion
(D), vascular smooth muscle (E), tooth mesenchyme (F), whisker pad (G) and Meckel's cartilage (H). Abbreviations: C, cornea; Cx, cortex; D, dermis; DE, dental epithelium;
DM, dental mesenchyme; DP, dermal papilla; E, epidermis; GE, ganglionic eminence; Le, lens; MC, Meckel cartilage; NC, nasal cavity; Nca, nasal capsule; NS, nasal septum;
Op, optic nerve; Re, retina; Ro, route of trigeminal nerve; T, tongue; Tg, trigeminal ganglion; UI, upper incisor. Scale bars: 1 mm in A, B, 0.1 mm in C–H.
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and migratory NCC, the major difference between theMef2c-F10N-Cre
and Wnt1-Cre lines appears to lie with respect to lineage tracing of
derivatives of migrating NCC in the calvarial bones (Fig. 9). Our data,
together with published reports of Wnt1-Cre;R26R embryos, indicate
that in addition to the frontal bone, theWnt1-Cre driver also labels the
medial part of the interparietal bone (Jiang et al., 2002; Yoshida et al.,
2008). In contrast, theMef2c-F10N-Cre lineage tracing does not appear
to include cells in the interparietal bone (Fig. 9B and D). Other than
that, the similarities between the Mef2c-F10N-Cre and Wnt1-Cre lines
are strong. The close concordance lends conﬁrmation that the Mef2c-
F10N-Cre transgene may serve as an independent tool to genetically
label or modify NCC and their derivatives.
The precise contribution of NCC to olfactory tissues, particularly
the olfactory epithelium and neurons remains unresolved. Recently
published P0-Cre, Pax7-Cre,Wnt1-Cre and Sox10-Venus lineage tracing
experiments have documented labeling of olfactory neurons and
olfactory ensheathing glia. However, a contribution of NCC to the
olfactory epithelium remains controversial (Barraud et al., 2010; Katoh
et al., 2011; Murdoch et al., 2010). GFP transgenic chick grafting
experiments suggest that NCC do not contribute to the olfactory
epithelium (Barraud et al., 2010), but more recent EGFP electropora-
tion experiments in chick embryos suggest that a few NCC do invade
the olfactory epithelium (Katoh et al., 2011). Interestingly, in Mef2c-
F10N-Cre;R26R embryos, olfactory ensheathing glia surrounding the
olfactory epithelium and within the olfactory bulb were labeled
(Fig. 8A and B), but neurons of the olfactory epithelium were not
(Fig. 2C, Fig. 5K, Fig. 7A, and Fig. 8B). Thus, our Mef2c-F10N-LacZ and
Mef2c-F10N-Cre embryo labeling data strongly supports the view that
NCC contribute to olfactory ensheathing glia but not to neurons of the
olfactory epithelium.
Fig. 8. Mef2c-F10N-Cre lineage labeling in the olfactory bulb. (A–D) Frontal sections through developing olfactory structures of an E14.5Mef2c-F10N-Cre;R26R embryo. (A–B)
X-gal staining and immunostaining for markers of mature neurons (Tuj1) and muscle (Actin). (C, D) High magniﬁcation images of olfactory bulb and nasal epithelium as
outlined in red dashed insets in (A, B) with X-gal staining directly detected by 633 nm ﬂuorescence emission in combination with antibody staining of mature neurons (Tuj1).
Abbreviations: NS, nasal septum; OB, olfactory bulb; OE, olfactory epithelium; ONL, olfactory nerve layer. Scale bars: 0.5 mm in A, 0.2 in B–D.
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In conclusion, theMef2c-F10N-LacZ transgenic line labels migrating
NCC that have delaminated from the neuroepithelium and continues
to predominantly mark neuronal and glial NCC derivatives in the PNS
and melanocytes in the skin throughout embryonic development. The
Mef2c-F10N-Cre similarly induces Cre recombination in NCC after their
delamination from the neuroectoderm. The ﬁnal distribution pattern
of indelibly labeled NCC is very similar to that of Wnt1-Cre-labeled
NCC. Therefore, our Mef2c-F10N transgenic lines provide useful new
tools and resources for lineage tracing and analyses of gene function in
migrating NCC independently of NCC formation.
Materials and methods
Generation of Mef2c-F10N-LacZ and Mef2c-F10N-Cre transgenic mice
Mef2c-F10N was cloned into the transgenic reporter plasmid
hsp68-LacZ (Kothary et al., 1989a; Kothary et al., 1989b) to generate
Mef2c-F10N-LacZ (De Val et al., 2008). Mef2c-F10N-Cre was made
by replacing the LacZ gene of Mef2c-F10N-LacZ with the Cre cDNA
from pBS185-CMV-Cre (Sauer and Henderson, 1990). To generate
transgenic mice, a 5.5-kb SalΙ fragment of Mef2c-F10N-LacZ and a
Fig. 9. Mef2c-F10N-Cre lineage labels calvarial bones of the skull and meninges and choroid plexus of the brain. (A), Dorsal view of the skull vault of an E18.5Mef2c-F10N-Cre;
R26R embryo stained with X-gal. (B–D) Skull double stained for X-gal and Alizarin red in dorsal (B) and lateral (C, D) views. (D), Higher magniﬁcation image of specimen in
(C). (E, F) Frontal sections through the forebrain region of an E14.5 embryo corresponding to inset in Fig. 7B. Distribution of β-galactosidase activity revealed by bright ﬁeld
microscopy and also by direct detection of far-red (633 nm) X-gal ﬂuorescence in conjunction with immunostaining for neural maturation, (Tuj1) and nuclei, (DAPI). Red
arrowheads in (A, C–E) indicate β-galactosidase activity of meninges covered cortex. White arrowheads in F indicate choroid plexus. Abbreviations: C1, C1 vertebra; C2, C2
vertebra; CS, coronal suture; Cx, cortex; E, eye; EO, exoccipital bone; F, frontal bone; GE, ganglionic eminence; IP, interparietal bone; IS, interfrontal suture; N, nasal bone; P,
parietal bone; SO, supraoccipital bone; Ve, ventricle. Scale bars: 1 mm in A–D, 0.2 in E, F.
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3.8-kb Not1/SalΙ fragment of Mef2c-F10N-Cre were gel puriﬁed,
ethanol precipitated and used for pronuclear injection into CBA;
B10 fertilized eggs.
Genotyping
Genotyping by PCR with LacZ and Cre speciﬁc probes was performed
by Transnetxy Inc.
β-galactosidase detection and bone staining. Mouse embryos were
dissected and ﬁxed in 1% formalin/0.1% PBS or 4% Paraformaldehyde
(PFA) 0.1% PBS or 0.2% glutalaldehyde/2% formalin/0.1% PBS for 15 min
(E7–8), 30 min (E9–10), 1 h (E11–12), 1.5 h (E13 and older) at 4 1C. The
strength of LacZ staining varied depending on ﬁxation with gluta-
raldehyde/formalin producing the strongest signal followed by PFA
and then formalin. Fixing with glutaraldehyde/formalin was the most
suitable for visualizing melanocytes, but was not used for co-immu-
noﬂuorescent staining because glutaraldehyde ﬁxation can result in
tissue autoﬂuorescence (Collins and Goldsmith, 1981). For whole-
mount X-gal staining, embryos were washed 315min in cold PBS
prior to β-galactosidase detection. For cryosection staining, embryos
Fig. 10. Mef2c-F10N-Cre lineage labels trunk NCC derivatives. (A, B) Transverse sections of an E14.5 Mef2c-F10N-Cre;R26R embryo at upper chest level imunostained to
detect cell linages labeled by Cre excision (β-gal) and endothelial cells (CD31). (B) High magniﬁcation images in A. White arrows indicate NCC in smooth muscle of the aorta.
(C–E) Transverse section at cardiac level stained for β-galactosidase activity (X-gal) and immunostained to identify NCC (SOX9), mature neurons (Tuj1), and muscle (Actin) (D,
E). Red arrow indicates expression in non-NCC cardiac tissue. (E) High magniﬁcation of inset in (C, D). (F) Section through adrenal gland of E14.5 embryo immunostained for
β-galactosidase, tyrosine hydroxylase (TH) and Tuj1. (G, H) LacZ and Alizarin red staining of E18.5 fore limb (G) and hind limb (H). (I–L) Section of gut stained for Cre excision
(β-gal) and for mature neurons (PHOX2B/Tuj1) (I, J), or for NCC and glia SOX10/neuroﬁlament (NF) (K, L). J, L, High magniﬁcation images of insets in I, J. White arrows indicate
triple overlapping expression. Abbreviations: AC, adrenal cortex; AM, adrenal medulla; Ao, aorta arch; At, atrium; CC, conotruncal seminlunar valve leaﬂets; Cl, clavicle; DRG,
dorsal root ganglion; DP, distal phalange; Fe, femure; Fi, ﬁbula, Gt, gut; H, humerus; IS, interventricular septum; LV, left ventricle, Lu, lung; N, nasal bone; NC, notochord; Oe,
esophagus; PP, proximal phalange; Ra, radius bone; Ri, rib; RV, right ventricle; Th, thymus; Ti, tibia; Tr, trachea; Ul, ulna bone; Sc, scapula bone; SC, spinal cord; SG,
sympathetic ganglion; Ve, vertebral body; VN trigeminal nerve. Scale bars: 0.5 mm in A, C, D, 0.1 mm in B, E, F, I–L, 1 mm in G, H.
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were washed with cold PBS, then processed through a graded series of
sucrose solutions 5%/10%/15%/20% in PBS, before being embedded in
2:1 mixture of 20% sucrose/OCT compound (Tissue-Tek) and stored at
80 1C until sectioned. β-galactosidase activity was detected with X-
gal solution (40 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, 2 mM MgCl, 0.01% sodium deoxycholate,
0.02% Nonidet P-40). For combined X-gal and Alizarin red staining,
E18.5 embryos were ﬁrst stained with X-gal and then stained with
0.005% Alizarin red S in 3% KOH (A5533, Sigma-Aldrich) to visualize
bone. For combined X-gal staining with immunostaining, slides were
ﬁrst stained with X-gal, then washed with PBS and post-ﬁxed with
10% formalin/PBS for 10 min, prior to antibody immunostaining. β-
galactosidase signal was detected under bright ﬁeld microscopy and
also ﬂuorescently via confocal microscopy as an emission signal in the
650–770 nm range (far red) after excitation at 633 nm (Levitsky et al.,
2013).
Immunoﬂuorescence. Dissected mouse embryos were ﬁxed in 4%
PFA/PBS for 2 h or 1% formalin overnight at 4 1C and then
embedded in OCT as described above. Frozen sections (10–14 mm)
were cut, then dried with a hair dryer for 30–60 s. Sections were
washed 35min in PBS, incubated in a blocking solution of 3%
bovine serum albumin (BSA)/0.01% Tween 20 in PBS (PBT) for 1 h at
room temperature, and then incubated with primary antibodies
overnight at 4 1C Antibodies used include mouse anti-Actin HHF35
(1/100, M0635, DAKO), mouse anti-AP2α (1/50, 3B5, Iowa hybridoma),
rabbit anti-β-galactosidase (1/2000–1/5000, #559761, Capple), goat
anti-β-galactosidase (1/2000–1/5000, #4600-1409, Biogenesis), mouse
anti-collagen ΙΙ (1/50, II-II6B3, Iowa hybridoma), chick anti-GFP (1/
1000, GFP-1020, Aves), rabbit anti-GFP (1/1000, A6455, Invitrogen),
mouse anti-Islet1/2 (1/10, 4D5, Iowa hybridoma), mouse anti-MSX1/2
(1/50, 4G1, Iowa hybridoma), mouse anti-neuroﬁlament (1/100, 2H3,
Iowa hybridoma), rabbit anti-p75 NGFR (1/500, G3231, Promega),
mouse anti-PAX3 (1/50, Iowa hybridoma), mouse anti-PAX7 (1/100,
Iowa hybridoma), rat anti-CD31 (1/100, #553370, BD pharmingen),
goat anti-PHOX2b (kindly provide form Dr. Enomoto), mouse anti-
SOX2 (1/100, MAB2018, R&D system), rabbit anti-SOX9 (1/500,
AB5535, Millipore), goat anti-SOX10 (1/100, AF2864, R&D system),
rabbit anti-Tuj1 (1/2000, PRB-435P, Covance) and rabbit anti-tyrosine
hydroxylase (1/100, #2792, Cell signaling). Following incubation with
primary antibodies, slides were washed 35min in PBS, and then
incubated with secondary antibodies for one hour at room temp-
erature. Secondary antibodies included donkey anti-goat, -mouse or
-rabbit ﬂuorescent Alexa Fluor 488, 546, 647 conjugated antibodies (1/
200, Invitrogen), DAPI was used to stain the nuclei (1/1000, Sigma).
Fluorescent confocal images were acquired using an LSM-510-VIS,
Upright Pascal or LSM-700 (Carl Zeiss).
Genome comparison. The UCSC genome browser (http://genome.
ucsc.edu/) was used to compare the Mef2c-F10N enhancer from
rat, rabbit, human, chicken, Xenopus tropicalis and zebraﬁsh.
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